Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731571 · ClinicalTrials.gov registry record
Toward High Fidelity Adaptive Radiotherapy in the Thorax
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 20
- Enrollment target
NCT04731571: Completed study, sponsored by Henry Ford Health System.
NCT04731571 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04731571 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Daily adaptive radiotherapy with individualized planning margins for thoracic and pelvic cancer patients will increase the potential of reducing dose to OARs, thereby reducing treatment-related toxicities and ultimately providing these patients with a better quality of life. Thus, the overarching objective of this work is to develop a CBCT-guided adaptive workflow and to measure the benefits to patients of the adaptive treatment paradigm utilizing patient reported outcomes in a first-of-kind study.
Primary Outcome
A set of treatment planning strategies were designed and retrospectively implemented for locally advanced, non-small cell lung cancer (NSCLC) patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2025-02-27 |
What the finished NCT04731571 record still lists
NCT04731571 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04731571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04731571 about?
NCT04731571 is a clinical study titled "Toward High Fidelity Adaptive Radiotherapy in the Thorax". Daily adaptive radiotherapy with individualized planning margins for thoracic and pelvic cancer patients will increase the potential of reducing dose to OARs, thereby reducing treatment-related toxicities and ultimately providing these patients with a better quality of life. Thus, the overarching ob...
What is the current status of trial NCT04731571?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-02-05. Estimated completion is 2025-02-27.
Who is sponsoring clinical trial NCT04731571?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI